|Articles|March 23, 2021
Superior Monoclonality Assurance for a Successful IND
Author(s)Berkeley Lights, Inc.
Used by leading pharma companies and CDMOs, the Beacon system offers an integrated end-to-end automated workflow for mammalian cell line development. Clones can be selectively enriched for unique phenotypes and multiple assays can be used to rapidly measure productivity of different antibody molecules.
Newsletter
Stay at the forefront of biopharmaceutical innovation—subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.
Related Content
Trending on BioPharm International
1
First-in-Human Study Validates Safety of Next-Generation mRNA–LNP Platform
2
How CDMO Alliances Can Provide End-to-End Service that Reduces Drug Development Time and Costs
3
FDA Clears PharmaResearch IND for Nano-Based Cancer Drug PRD-101
4
High-Dose Nusinersen Slows Neurodegeneration in SMA Patients, Study Shows
5